Mental state · schizophrenia
1 finding from 1 review
Mental state · schizophrenia
1 finding from 1 review
Mental state · schizophrenia
1 finding from 1 review
Reduction of TTM symptom severityMassachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) · adults with trichotillomania
1 finding from 1 review
Reduction of TTM symptom severityMassachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) · adults with trichotillomania
1 finding from 1 review
Reduction of TTM symptom severityMassachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) · children and adolescents with trichotillomania
1 finding from 1 review
Reduction of TTM symptom severityMassachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) · adults with trichotillomania
1 finding from 1 review
Reduction of TTM symptom severityMassachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) · adults with trichotillomania
1 finding from 1 review
Reduction of TTM symptom severityMassachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) · adults with trichotillomania
1 finding from 1 review
Reduction of TTM symptom severityMassachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) · children with trichotillomania
1 finding from 1 review
Reduction of TTM symptom severityMassachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) · adults with trichotillomania
1 finding from 1 review
Adverse effects (general symptoms) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (general symptoms) compared with levetiracetam (low certainty).
1 finding from 1 review
Overall survival (baseline risks for low‐ and high‐risk groups in the control arm were estimated at 1 year) · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in overall survival (baseline risks for low‐ and high‐risk groups in… compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
1‐Year survival rate · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in 1‐year survival rate compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
Response rate · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in response rate compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
Adverse events: neurotoxicity (grade 3/4) ( · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin probably leads to higher grade III or IV neurotoxicity compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin probably leads to higher grade III or IV thrombocytopenia compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
Grade III or IV renal toxicity · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in grade III or IV renal toxicity compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
50% reduction in generalised‐onset seizure frequency Not measured · patients with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functioning: clinically important change in general functioning, as defined by individual studies · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found